Dynavax Technologies Corp (NASDAQ: DVAX) on Tuesday, plunged -1.92% from the previous trading day, before settling in for the closing price of $13.04. Within the past 52 weeks, DVAX’s price has moved between $9.74 and $15.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 239.63%. The company achieved an average annual earnings per share of 496.00%. With a float of $130.91 million, this company’s outstanding shares have now reached $131.34 million.
Let’s determine the extent of company efficiency that accounts for 408 employees. In terms of profitability, gross margin is 82.85%, operating margin of -3.42%, and the pretax margin is 9.29%.
Dynavax Technologies Corp (DVAX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Dynavax Technologies Corp is 0.42%, while institutional ownership is 103.66%. The most recent insider transaction that took place on May 31 ’24, was worth 43,127. In this transaction Director of this company sold 3,615 shares at a rate of $11.93, taking the stock ownership to the 36,905 shares. Before that another transaction happened on Mar 01 ’24, when Company’s Chief Accounting Officer sold 20,526 for $12.78, making the entire transaction worth $262,322. This insider now owns 0 shares in total.
Dynavax Technologies Corp (DVAX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 496.00% per share during the next fiscal year.
Dynavax Technologies Corp (NASDAQ: DVAX) Trading Performance Indicators
Dynavax Technologies Corp (DVAX) is currently performing well based on its current performance indicators. A quick ratio of 12.34 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.45. Likewise, its price to free cash flow for the trailing twelve months is 74.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.13, a number that is poised to hit 0.04 in the next quarter and is forecasted to reach 0.25 in one year’s time.
Technical Analysis of Dynavax Technologies Corp (DVAX)
Looking closely at Dynavax Technologies Corp (NASDAQ: DVAX), its last 5-days average volume was 1.61 million, which is a drop from its year-to-date volume of 2.15 million. As of the previous 9 days, the stock’s Stochastic %D was 89.30%. Additionally, its Average True Range was 0.43.
During the past 100 days, Dynavax Technologies Corp’s (DVAX) raw stochastic average was set at 73.49%, which indicates a significant increase from 57.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.64% in the past 14 days, which was higher than the 38.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.69, while its 200-day Moving Average is $11.59. However, in the short run, Dynavax Technologies Corp’s stock first resistance to watch stands at $12.99. Second resistance stands at $13.20. The third major resistance level sits at $13.30. If the price goes on to break the first support level at $12.68, it is likely to go to the next support level at $12.58. Now, if the price goes above the second support level, the third support stands at $12.37.
Dynavax Technologies Corp (NASDAQ: DVAX) Key Stats
Market capitalization of the company is 1.68 billion based on 131,455K outstanding shares. Right now, sales total 232,280 K and income totals -6,390 K. The company made 80,630 K in profit during its latest quarter, and 17,590 K in sales during its previous quarter.
